Loading...
Market
What will be Ultragenyx's GTX-102 worldwide revenue in FY28?
2
Resolution / Starting Odds
Less than $1,100 million • 25%
$1,100 million to $1,251 million • 25%
$1,251 million to $1,400 million • 25%
More than $1,400 million • 25%
Ultragenyx financial reports
Story
Ultragenyx ($RARE) Announces Successful End-of-Phase 2 Meeting with FDA for GTX-102 Angelman Syndrome
Jul 18, 2024, 01:49 AM
Ultragenyx Pharmaceutical Inc. ($RARE) has announced a successful end-of-Phase 2 meeting with the FDA for its GTX-102 Angelman Syndrome program. The company is set to initiate a Phase 3 study by the end of this year, with primary and secondary endpoints aligned with the FDA. The primary endpoint will focus on Bayley-4 cognition, while the secondary endpoint will be the Multi-Domain Responder Index (MDRI). Ultragenyx's GTX-102 gene therapy has shown early efficacy and targets a market of approximately 60,000 children suffering from Angelman Syndrome. The company projects worldwide revenue for GTX-102 to reach $475 million in FY27, $1,251 million in FY28, and $1,640 million in FY29, valuing the asset at approximately $43 per share. The pivotal study is expected to start in Q4 this year.
View original story
Similar markets
Less than $500 million • 25%
$500 million to $1 billion • 25%
$1 billion to $2 billion • 25%
More than $2 billion • 25%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Below $100 million • 25%
$100 million to $500 million • 25%
$500 million to $1 billion • 25%
Above $1 billion • 25%
Less than 10% • 25%
10% to 25% • 25%
25% to 50% • 25%
More than 50% • 25%
Less than $500 million • 25%
$500 million to $1 billion • 25%
$1 billion to $1.5 billion • 25%
More than $1.5 billion • 25%
Below $500M • 33%
$500M - $1B • 33%
Above $1B • 34%
Less than $200 million • 25%
$200 million to $400 million • 25%
$400 million to $600 million • 25%
More than $600 million • 25%
Less than $300M • 33%
$300M - $500M • 33%
More than $500M • 33%
Less than $500 million • 25%
$500 million to $1 billion • 25%
$1 billion to $2 billion • 25%
More than $2 billion • 25%